Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Clinical evidence

Advance-HTN

65 evidence topics · 14 sources

Objective
Location and study date
Study design
Trial periods and their durations in the trial presentation
PeriodQuoted record
Screening“2 weeks”
Single-blind run-in on the standardized regimen“3 weeks”
Randomized double-blind treatment“12 weeks”
After the end of treatment“Open-label extension”; “2-week end of study visit”; “4-week washout”
Eligibility criteria
Blood pressure, medication, and laboratory thresholds in the trial presentation
CriterionQuoted record
Background antihypertensive medications at screening“2 - 5 BP medications”
Office blood pressure at screening“SBP 140 to 180 mm Hg, or DBP 90 to 110 mm Hg”
24-hour ambulatory blood pressure before randomization“SBP 130 to 180 mm Hg, or DBP > 80 mm Hg”
Serum sodium“Na+ ≥ 135”
Estimated glomerular filtration rate“eGFR ≥ 45”
Treatment
Study outcomes
Rationale for using change in 24-hour ambulatory systolic blood pressure as the primary endpoint
Registered secondary outcome measures in the ClinicalTrials.gov record
Outcome measureTime frame
“Change from baseline in 24-hour average ABPM SBP at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo”“Baseline to Week 4”
“Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo”“at Week 4”
“Change from baseline in 24-hour average ABPM SBP at Week 4 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo”“Baseline to Week 4”
“Change from baseline in automated office BP (AOBP) SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at Week 4 (within-subjects analysis)”“Baseline to Week 12”
“Change from baseline in 24-hour average ABPM SBP at Week 4, by number of AHT medications in the standardized AHT regimen (2 and 3) in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo”“Baseline to Week 4”
“Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 12 in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo”“Baseline to Week 12”
“Change from baseline in 24-hour average ABPM SBP at Week 12 by obesity status in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo”“Baseline to Week 12”
“Change from baseline in daytime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo”“Baseline to Week 4 and Week 12”
“Change from baseline in AOBP SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo”“Baseline to Week 4 and Week 12”
“Change from baseline in nighttime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo”“Baseline to Week 4 and Week 12”
“Change from baseline in 24-hour average ABPM SBP at Week 12, in subjects randomized to lorundrostat (pooled dosages) compared to subjects randomized to placebo”“Baseline to Week 12”
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and statistical power

No evidence found.

Description of analysis sets
Results
Participant disposition
Baseline characteristics
Participant characteristics by treatment group in the trial presentation
CharacteristicPlaceboLorundrostat 50 mgLorundrostat 50 to 100 mg
Age (years)“59”“61”“61”
Women (%)“35%”“40%”“44%”
Black or African-American (%)“46%”“53%”“58%”
BMI (kg/m2)“32”“31”“32”
eGFR (randomization)“74”“77”“76”
Office BP (screening)“155/91”“153/88”“152/89”
24-hour ABPM (randomization)“141/87”“141/86”“141/87”
Efficacy results
Key secondary end point: 24-hour average systolic blood pressure below 125 mm Hg at week 4
GroupProportion with 24-hour average SBP <125 mm Hg at week 4
Placebo“18%”
Lorundrostat 50 mg (all)“41%”
Odds ratio (95% CI)“3.3 (1.4 to 7.8) P < 0.001”
Key secondary end point: change at week 4 by number of background medications
Background medicationsPlacebo nPlacebo change (mm Hg)Lorundrostat nLorundrostat change (mm Hg)Placebo-adjusted difference
2“n = 60”“-5.1”“n = 117”“-11.2”“-6.1 (-10.8 to -1.4) P = 0.001”
3“n = 34”“-7.2”“n = 71”“-11.8”“-4.6 (-10.6 to 1.5) P = 0.060”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events by treatment group in the trial presentation
Adverse eventPlaceboLorundrostat 50 mgLorundrostat 50 to 100 mg
Any serious AE“2%”“6%”“8%”
Any study-drug related serious AE“0”“2%”“1%”
Hypotension“3%”“9%”“8%”
Hyponatremia“6%”“9%”“11%”
Hyperkalemia (>6.0 mmol/L), single value“0”“5%”“7%”
Hyperkalemia (>6.0 mmol/L), confirmed via per protocol repeat testing“0”“2%”“3%”
Study limitations
Summary

Advance-HTN was a 12-week phase 2 trial (the presentation calls it a “Phase 2b trial”) in 285 randomized participants at sites in the United States only (104 locations in the registry record; 103 sites in the presentation). Every participant was switched to a standardized regimen of a diuretic, olmesartan, and, for those previously on 3 to 5 drugs, amlodipine, so the results describe lorundrostat added to that regimen and may differ from its effect on top of usual background therapy; the presenters list the need for “additional data using office blood pressure on top of usual care” from Launch-HTN as a limitation. Of 926 participants who started the standardized regimen, 641 were ineligible for randomization (53% because of the ambulatory blood pressure criterion), which selects a population with confirmed uncontrolled hypertension on a standardized regimen.

The 50 to 100 mg dose-adjustment strategy produced a smaller placebo-adjusted reduction at week 12 (-6.5 mm Hg) than the stable 50 mg dose (-7.9 mm Hg), and 19 participants were escalated to 100 mg, so the trial gives limited information on the 100 mg dose. The week 4 subgroup on 3 background medications (71 lorundrostat and 34 placebo participants) had a placebo-adjusted difference of -4.6 mm Hg with a confidence interval that crossed zero (P = 0.060). The placebo group had a 24-hour systolic reduction of 7.4 mm Hg at week 12.

Single-value potassium above 6.0 mmol/L occurred in 5.3% and 7.4% of the two lorundrostat groups (2.1% and 3.2% after confirmation by repeat testing). The trial was “Not head-to-head with other classes of antihypertensive medications” and “Not a cardiovascular or kidney outcome trial”. As of November 2026 no posted results were located in the registry record, and participant disposition after randomization, discontinuations for adverse events, mean changes in potassium, sodium, and eGFR, and daytime, nighttime, and office blood pressure results by arm are not reported in the publication abstract, the presentation, the registry record, or the company releases.